ValiRx's sale of Finnish subsidiary will free up resources
The group will retain the licence to use TRAC technology (transcript analysis with the aid of affinity capture) in its development of therapeutic candidates.
Company
ValiRx PLC
LON:VAL
ValiRx is a drug development company, which focuses on the translation of scientific innovation into clinical candidates for cancer, related conditions and women’s health. The company's specialised business model connects science, finance and commerce to accelerate early-stage drug development. It identifies proprietary and novel drug candidates with the potential to improve patient lives, providing the expertise and investment required for optimised development and value creation.
310 stories · page 13 of 16
FTSE 100 Index rises as Herencia gets in the money
Chilean copper miner did financing deals with two shareholders
FTSE100 heads north; Iofina bolsters small caps
FTSE AIM 100 was up 0.26% to 3,512, while the FTSE AIM All share gained 0.26% to stand at 745.290
ValiRx starts preparations for efficacy trial of cancer drug
ValiRx has also started preparatory work on a full efficacy study (phase III) of the drug in prostate cancer treatment.
Proactive new highlights: Amur Minerals, Fox Marble, Optibiotix, Sirius Minerals and more...
Amur Minerals has pitched the potential of its Kun-Manie nickel project in Far East Russia to potential investors in Korea.
Pharma small-caps get shot in arm from antibiotic report
Pharma company shares rise as report urges action to develop super-bug treatments
ValiRx advancing both lead compounds
A highlight of the year gone was Phase l/ll clinical trial of VAL201, which confirmed the compound was well tolerated and shown a high degree of safety.
Risers and Fallers: Pipehawk, Formation Group, Mobile Streams Risers...
Major share price risers and fallers in London at 3.30pm
FTSE 100 tumbles but Aim stocks make progress
People who measure such things say the chances of a rate hike in June have risen above 30%
ValiRx PLC readies for phase II clinical trial of lead cancer drug
The study will assess efficacy, safety and tolerability in people with the non-small cell variant of the disease where at least one form of chemotherapy has failed.
ValiRx making progress on several fronts
Life sciences firm ValiRx has been making progress on its lead drugs...
Proactive news highlights: ANGLE, Eland Oil & Gas, Fastjet, Obtala, Tekcapital and more...
Fastjet agrees to early lease termination, ANGLE's cancer detection device takes off and Obtala agrees to full settlement.
Risers & Fallers: Petro Matad, Avocet Mining, ASA Resources...
Major share price risers and fallers in London at 4.00pm
ValiRx joint venture awarded second US patent
The drug is targeting non-small-cell lung adenocarcinoma, the most common form of the disease.
Risers and fallers: Harvest Minerals, Norcon, Watchstone Group...
Image Scan's losses slashed. Cloudbuy rises on contract win. Kolar Gold's new broker raises fears of impending share issue.